Question to the Department of Health and Social Care:

To ask Her Majesty's Government whether, other than Evusheld, they are aware of any monoclonal antibody treatment that can protect the clinically extremely vulnerable through pre-exposure prophylaxis (PREP) against Omicron and its variants; and, if so, to list them.

The Department’s Antivirals and Therapeutics Taskforce is scoping the potential for pre-exposure prophylaxis with experts from the Prophylaxis Oversight Group, the UK Health Security Agency and the multi-agency group RAPID C-19.

The Medicines and Healthcare products Regulatory Agency has approved two such products - Evusheld and Ronapreve. However, treatments must demonstrate sufficient efficacy against Omicron and new variants. Ronapreve has been withdrawn from general use as it has since been found to be ineffective against the Omicron variant. We are therefore gathering data on how Evusheld performs against new variants.